InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.140 -0.02 (-12.50%)+
Announcement
Release
26 Feb 2026 8:16AM
Price at Release
$0.160
Full Release
download
Summary
Nova Eye Medical Limited reported significant sales growth and improvements in their financial performance for the first half of the fiscal year ending December 2025. The company achieved a record half-year revenue of US$11 million, reflecting a 31% increase from the previous year, primarily driven by strong sales in the United States and expanding markets outside the USA. Nova Eye Medical successfully improved its EBITDA, reducing its loss by A$2.0 million to A$2.2 million, attributed to better gross margins, operating leverage, and cost management. Their gross margin improved to 70% due to enhanced production efficiency and pricing strategies, while operating expenses as a percentage of revenue declined. The company also achieved a positive EBITDA by December 2025, aligning with its guidance. For the full fiscal year 2026, Nova Eye reaffirms its sales revenue guidance of US$21–24 million, excluding China, and targets a breakeven EBITDA in the second half of the fiscal year. Overall, the strategic investments in clinical data and operational improvements have positioned the company for sustained growth.
Key Points
  • Record half-year revenue of US$11 million, up 31% year-on-year.
  • Improved EBITDA, reducing the loss by A$2.0 million to A$2.2 million.
  • Gross margin increased to 70%.
  • Positive EBITDA achieved in December 2025.
  • Sales growth driven by the United States market and expansion outside USA.
  • FY26 sales revenue guidance reaffirmed at US$21–24 million, excluding China.
  • Targeting breakeven EBITDA in H2FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.